Eli Lilly will pay $6.75 per share upfront for AtaiBeckley, plus $2.50 per share tied to regulatory and clinical targets.
Eli Lilly agreed to purchase psychedelic drug developer AtaiBeckley for $6.75 per share in cash, valuing the deal at $2.8 billion. The agreement includes up to $2.50 per share in contingent value rights linked to clinical and regulatory milestones, bringing total potential consideration to $3.8 billion.
The upfront payment represents a premium to AtaiBeckley’s recent trading levels. The deal underscores growing interest in psychedelic-based therapies for mental health conditions, an area where Lilly has been expanding its pipeline.
Shares of AtaiBeckley surged 30% following the announcement, reflecting investor confidence in the transaction’s valuation and strategic fit.